Stocksigma LogoStocksigma Logo

Welcure Drugs FY26: Posts Net Loss Amid Auditor's Emphasis of Matter

Welcure Drugs reported a net loss of Rs 549.01 Lacs for the year ended 31st Mar'26, against a profit of Rs 217.01 Lacs in the previous year

Welcure Drugs FY26: Posts Net Loss Amid Auditor's Emphasis of Matter

Welcure Drugs & Pharmaceuticals Ltd 路 Financial Result 路 30 May 2026, 1:39 am

Welcure Drugs FY26: Posts Net Loss Amid Auditor's Emphasis of Matter Welcure Drugs reported a net loss of Rs 549.01 Lacs for the year ended 31st Mar'26, against a profit of Rs 217.01 Lacs in the previous year. For Q4 FY26, the company posted a net loss of Rs 4,986.14 Lacs. The statutory auditor issued an unmodified opinion but included an "Emphasis of Matters" section, highlighting an inability to verify the existence and valuation of inventory (Rs 14,352.36 Lacs), genuineness of certain sales, and recoverability of trade receivables and unconfirmed supplier advances (Rs 15,126.13 Lacs).

Original exchange filing (PDF)

More announcements from Welcure Drugs & Pharmaceuticals Ltd

All Welcure Drugs & Pharmaceuticals Ltd announcements